Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies

Haemophilia

Volumn 21, Issue 5, 2015, Pages 653-658

  Ichinose, Akitada ^a   Osaki, T ^a   Souri, M ^a   Matsushita T , ^b   Urano T , ^b   Ieko M , ^b   Tamai Y , ^b   Ito T , ^b   Kawamae K , ^b   Yamamoto M , ^b   Madoiwa S , ^b   Kurosawa H , ^b   Ogawa Y , ^b   Yatomi Y , ^b   Hanafusa N , ^b   Kawasugi K , ^b   Ishida F , ^b   Kitajima I , ^b   Asakura H , ^b   Hosono N , ^b   Mouri H , ^b   Kobayashi T , ^b   Wada H , ^b   Miyata S , ^b   Kashiwagi H , ^b   Ikeda M , ^b   Yukawa M , ^b   Higasa S , ^b   Hato T , ^b   Okamoto K , ^b   Okamura T , ^b   Uchiba M , ^b   Hashiguchi T , ^b   Maruyama I , ^b   more..

^a YAMAGATA UNIVERSITY   (Japan)

^b NONE

Author keywords

Autoimmune disease; Chronic intractable disease; Haemostatic therapy; Immunosuppressive treatment; Life threatening bleeding disorder; Nationwide survey

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 8 ANTIBODY; CYCLOPHOSPHAMIDE; PREDNISOLONE; RITUXIMAB; BLOOD CLOTTING FACTOR 13; HEMOSTATIC AGENT;

ADULT; AGE; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; FEMALE; GENDER; HAEMORRHAPHILIA; HEMOSTASIS; HUMAN; JAPANESE (PEOPLE); MALE; MIDDLE AGED; MORTALITY; MUSCLE BLEEDING; PRIORITY JOURNAL; PROGNOSIS; SKIN BLEEDING; SURVIVAL; SYMPTOM; TREATMENT OUTCOME; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOIMMUNE DISEASES; HEMOPHILIA A; IMMUNOLOGY; SURVIVAL ANALYSIS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FACTOR XIII; FEMALE; HEMOPHILIA A; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84942191869     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12677     Document Type: Article

References (28)

1. Nugent DJ. Prophylaxis in rare coagulation disorders - factor XIII deficiency. Thromb Res 2006; 11851: S23-8.
2. Kohler HP, Ichinose A, Seitz R et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-6.
3. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-70.
4. Biswas A, Ivaskevicius V, Thomas A et al. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 2014; 34: 160-6.
5. Shetty S, Shelar T, Mirgal D et al. Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 2014; 20: 575-81.
6. Egbring R, Kröniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996; 22: 419-25.
7. Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol 2001; 5: 389-404.
8. Collins PW, Hirsch S, Baglin TP et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-7.
9. Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011; 37: 382-8.
10. Lorand L. Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins. In: Green D ed. Anticoagulants, Physiologic, Pathologic and Pharmacologic. Boca Raton, FL: CRC Press, 1994: 169-91.
11. Ichinose A, Souri M. Japanese Collaborative Research Group on 'Acquired haemorrha-philia due to factor XIII deficiency'. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105: 925-7.
12. Teruya J, Kinoshita T, Yoshimura Y et al. An inhibitor to factor VIII interacting with its activated catalytic subunit. Rinsho Ketsueki 1986; 27: 1680-7, Japanese.
13. Nakamura S, Kato A, Sakata Y et al. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68: 313-9.
14. Ino H, Shiomi Z, Hayami H et al. A case suspected of acquired factor XIII abnormality [abstract]. Int J Hematol 1984; 47: 650, Japanese.
15. Kato A, Saito T, Kiyose H et al. Successful steroid therapy of acquired coagulation factor XIII insufficiency [abstract]. Rinsho Ketsueki 1988; 29: 908, Japanese.
16. Nakazawa M, Iida R, Tanoue K et al. Successful gastrectomy in a patient with inhibitor activities to factor XIII and phospholipid-mediated clotting time [abstract]. Thromb Haemost 1997; 35: PS-137.
17. Shinkai K, Nishiwaki H, Takagi A et al. Hemostatic management of severe hemorrhage in a case with factor XIII inhibitor [abstract]. Int J Hematol 1996; 63(Suppl. 1): 291, Japanese.
18. Kohro J, Nakamura K, Yamamoto T et al. A case of SLE complicated by coagulation factor XIII deficiency [abstract]. Ryumachi 1997; 37: 326, Japanese.
19. Kanto H, Kurikawa Y, Koseki M et al. A case of annular elastolytic giant cell Granuloma Associated with acquired plasma factor XIII deficiency. Jpn J Dermatol 1998; 108: 747-54, Japanese.
20. Souri M, Koseki-Kuno S, Takeda N et al. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol 2008; 87: 60-8.
21. 2-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies. Int J Hematol 2012; 95: 47-50.
22. Wada H, Souri M, Matsumoto R et al. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency. Thromb Haemost 2013; 109: 661-8.
23. Ajzner E, Muszbek L. Kinetic spectrophotometric factor XIII activity assays: the subtraction of plasma blank is not omissible [corrected]. J Thromb Haemost 2004; 2: 2075-7.
24. Ajzner E, Schlammadinger A, Kerényi A et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-5.
25. Green D. Factor VIII inhibitors: a 50-year perspective. Haemophilia 2011; 17: 831-8.
26. Huth-Kühne A, Baudo F, Collins P et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-75.
27. Ogawa Y, Mihara M, Souri M et al. Complete remission achieved by steroid pulse therapy following rituximab treatment in a case with autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Thromb Haemost 2014; 112: 831-3.
28. Sugiyama H, Uesugi H, Suzuki S, Tanaka K, Souri M, Ichinose A. Aggressive fatal case of autoimmune hemorrhaphilia resulting from anti-factor XIII antibodies. Blood Coagul Fibrinolysis 2013; 24: 85-9.